Reviva to Present at the 36th Annual ROTH Conference

CUPERTINO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the 36th Annual ROTH Conference, taking place March 17-19, 2024, in Dana Point, CA.

36th Annual ROTH Conference Format: Presentation and one-on-one investor meetingsDate: Tuesday, March 19, 2024Time: 2:00 p.m. PTLocation: Dana Point, CAWebcast Link: Click Here

Please contact your ROTH representative to register for the conference and schedule a one-on-one meeting with Reviva management.

About Reviva Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:Reviva Pharmaceuticals Holdings, Inc.Laxminarayan Bhat, PhD www.revivapharma.com

Investor Relations Contact:LifeSci Advisors, LLCBruce Mackle[email protected]

Media Contact:Kristin Politi[email protected](646) 876-4783

You May Also Be Interested In

• NEXE Innovations Reports Q4 and Fiscal 2026 Results and Business Update
• Craftsman Concrete Floors Publishes 2026-2027 Technical Guide to ESD Flooring Installation, Testing and Closeout
• Suphini Empowers Prestigious Italian Dance Shoe Brand’s Product Line Upgrade and European Market Expansion